Skip to content

Released Mar 27, 2025, after the close

10-K filed Mar 27, 2025, 86 days after period end · 0000950170-25-046125

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$52.00Kderived−76.7% vs Q4 2023−20.0% vs Q3 2024
Net Income-$20.89MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$21,725,000N/M
Operating Cash Flowderived-$23,401,000N/M
Margins · derived
Operating margin-41778.8%
Net margin-40169.2%

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue$52.00K$223.00K$278.00K—
Net Income-$20.89M$51.21M$26.79M-$29.30M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR